AKL4 is being considered for the treatment of Alzheimer’s disease where there is an increasing view that inflammation plays a pivotal role in the development of the disease.
Other diseases linked to inflammation are also being investigated, including rheumatoid arthritis:
Neutrophils play a key role in tissue damage seen in RA and a number of other autoimmune diseases. APPA has been shown to moderate several of these functions so has the potential to be a future treatment for RA.
In-vitro work is currently underway investigating AKL4’s role in the treament of Scleroderma, a rare connective tissue disease.